Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial-Reference-Cited by-同舟云学术

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Published:2022-06 Issue:6 Volume:10 Page:418-429
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Heise Tim,Mari Andrea,DeVries J Hans,Urva Shweta,Li Jing,Pratt Edward John,Coskun Tamer,Thomas Melissa K,Mather Kieren J,Haupt Axel,Milicevic Zvonko

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials;Min;Diabetes Ther,2021

2. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes;Frías;N Engl J Med,2021

3. From the incretin concept and the discovery of GLP-1 to today's diabetes therapy;Holst;Front Endocrinol (Lausanne),2019

4. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease;Baggio;Mol Metab,2021

5. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans;Finan;Sci Transl Med,2013

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis;Cureus;2024-09-09

2. Tirzepatide a novel anti diabetic molecule unfold dual action;Discover Public Health;2024-09-05

3. The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies;Diseases;2024-09-05

4. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19

5. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes;JAMA Network Open;2024-08-12